Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Aspirin and non steroidal anti-inflammatory drugs, NSAIDS, should be stopped 7 to 10 days prior to surgery. The reason for discontinuing these medications is that they can increase bleeding at the time of surgery.
Celebrex is a COX II Inhibitor are a fairly new class of NSAIDS.
Confusion arises because in studies Celebrex does not cause increased
However to be safe some surgeons recommend to stop Celebrex 7 to 10 days before surgery.
In general, Celebrex can be restarted the day after the procedure once the risk of bleeding is over.
According to the National Academy of Sciences , Philip Needleman , who was vice president of Monsanto in 1989 and president of Searle in 1993  oversaw research into COX-2 that led to the development of the anti-inflammatory drug celecoxib (Celebrex).  He became senior executive vice president and chief scientist of Pharmacia from 2000 to 2003.  Celecoxib was discovered and  developed by G. D. Searle & Company and was approved by the FDA on December 31, 1998.  It was co-promoted by Monsanto Company (parent company of Searle) and Pfizer under the brand name Celebrex. Monsanto merged with Pharmacia , from which the Medical Research Division was acquired by Pfizer, giving Pfizer ownership of Celebrex. The drug was at the core of a major patent dispute that was resolved in Searle's favor (later Pfizer) in 2004.   In University of Rochester v. Searle & Co. , 358 916 (Fed. Cir. 2004), the University of Rochester claimed that United States Pat. No. 6,048,850 (which claimed a method of inhibiting COX-2 in humans using a compound, without actually disclosing what that compound might be) covered drugs such as celecoxib. The court ruled in favor of Searle, holding in essence that the University had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid.